table of content
1 Kidney Cancer Drugs Market Overview
1.1 Product Overview and Scope of Kidney Cancer Drugs
1.2 Kidney Cancer Drugs Segment by Type
1.2.1 Global Kidney Cancer Drugs Sales Growth Rate Comparison by Type (2023-2030)
1.2.2 Angiogenesis Inhibitors
1.2.3 mTOR Inhibitors
1.2.4 Monoclonal Antibodies
1.2.5 Cytokine Immunotherapy (IL-2)
1.3 Kidney Cancer Drugs Segment by Application
1.3.1 Global Kidney Cancer Drugs Sales Comparison by Application: (2023-2030)
1.3.2 Renal Cell Carcinoma (RCC)
1.3.3 Transitional Cell Carcinoma (TCC)
1.4 Global Kidney Cancer Drugs Market Size Estimates and Forecasts
1.4.1 Global Kidney Cancer Drugs Revenue 2018-2030
1.4.2 Global Kidney Cancer Drugs Sales 2018-2030
1.4.3 Kidney Cancer Drugs Market Size by Region: 2018 Versus 2022 Versus 2030
2 Kidney Cancer Drugs Market Competition by Manufacturers
2.1 Global Kidney Cancer Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Kidney Cancer Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Kidney Cancer Drugs Average Price by Manufacturers (2018-2023)
2.4 Manufacturers Kidney Cancer Drugs Manufacturing Sites, Area Served, Product Type
2.5 Kidney Cancer Drugs Market Competitive Situation and Trends
2.5.1 Kidney Cancer Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Kidney Cancer Drugs Players Market Share by Revenue
2.5.3 Global Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Kidney Cancer Drugs Retrospective Market Scenario by Region
3.1 Global Kidney Cancer Drugs Retrospective Market Scenario in Sales by Region: 2018-2023
3.2 Global Kidney Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2018-2023
3.3 North America Kidney Cancer Drugs Market Facts & Figures by Country
3.3.1 North America Kidney Cancer Drugs Sales by Country
3.3.2 North America Kidney Cancer Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Kidney Cancer Drugs Market Facts & Figures by Country
3.4.1 Europe Kidney Cancer Drugs Sales by Country
3.4.2 Europe Kidney Cancer Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Kidney Cancer Drugs Sales by Region
3.5.2 Asia Pacific Kidney Cancer Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Kidney Cancer Drugs Market Facts & Figures by Country
3.6.1 Latin America Kidney Cancer Drugs Sales by Country
3.6.2 Latin America Kidney Cancer Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Kidney Cancer Drugs Sales by Country
3.7.2 Middle East and Africa Kidney Cancer Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Kidney Cancer Drugs Historic Market Analysis by Type
4.1 Global Kidney Cancer Drugs Sales Market Share by Type (2018-2023)
4.2 Global Kidney Cancer Drugs Revenue Market Share by Type (2018-2023)
4.3 Global Kidney Cancer Drugs Price by Type (2018-2023)
5 Global Kidney Cancer Drugs Historic Market Analysis by Application
5.1 Global Kidney Cancer Drugs Sales Market Share by Application (2018-2023)
5.2 Global Kidney Cancer Drugs Revenue Market Share by Application (2018-2023)
5.3 Global Kidney Cancer Drugs Price by Application (2018-2023)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bayer Kidney Cancer Drugs Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Roche Kidney Cancer Drugs Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 GlaxoSmithKline Kidney Cancer Drugs Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis Kidney Cancer Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Kidney Cancer Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott Laboratories
6.6.1 Abbott Laboratories Corporation Information
6.6.2 Abbott Laboratories Description and Business Overview
6.6.3 Abbott Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Abbott Laboratories Kidney Cancer Drugs Product Portfolio
6.6.5 Abbott Laboratories Recent Developments/Updates
6.7 Active Biotech
6.6.1 Active Biotech Corporation Information
6.6.2 Active Biotech Description and Business Overview
6.6.3 Active Biotech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Active Biotech Kidney Cancer Drugs Product Portfolio
6.7.5 Active Biotech Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Amgen Kidney Cancer Drugs Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 Argos Therapeutics
6.9.1 Argos Therapeutics Corporation Information
6.9.2 Argos Therapeutics Description and Business Overview
6.9.3 Argos Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Argos Therapeutics Kidney Cancer Drugs Product Portfolio
6.9.5 Argos Therapeutics Recent Developments/Updates
6.10 ArQule
6.10.1 ArQule Corporation Information
6.10.2 ArQule Description and Business Overview
6.10.3 ArQule Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 ArQule Kidney Cancer Drugs Product Portfolio
6.10.5 ArQule Recent Developments/Updates
6.11 AVEO Pharmaceuticals
6.11.1 AVEO Pharmaceuticals Corporation Information
6.11.2 AVEO Pharmaceuticals Kidney Cancer Drugs Description and Business Overview
6.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 AVEO Pharmaceuticals Kidney Cancer Drugs Product Portfolio
6.11.5 AVEO Pharmaceuticals Recent Developments/Updates
6.12 Bionomics
6.12.1 Bionomics Corporation Information
6.12.2 Bionomics Kidney Cancer Drugs Description and Business Overview
6.12.3 Bionomics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Bionomics Kidney Cancer Drugs Product Portfolio
6.12.5 Bionomics Recent Developments/Updates
6.13 Bristol-Myers Squibb
6.13.1 Bristol-Myers Squibb Corporation Information
6.13.2 Bristol-Myers Squibb Kidney Cancer Drugs Description and Business Overview
6.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Bristol-Myers Squibb Kidney Cancer Drugs Product Portfolio
6.13.5 Bristol-Myers Squibb Recent Developments/Updates
6.14 Cerulean Pharma
6.14.1 Cerulean Pharma Corporation Information
6.14.2 Cerulean Pharma Kidney Cancer Drugs Description and Business Overview
6.14.3 Cerulean Pharma Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Cerulean Pharma Kidney Cancer Drugs Product Portfolio
6.14.5 Cerulean Pharma Recent Developments/Updates
6.15 Exelixis
6.15.1 Exelixis Corporation Information
6.15.2 Exelixis Kidney Cancer Drugs Description and Business Overview
6.15.3 Exelixis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Exelixis Kidney Cancer Drugs Product Portfolio
6.15.5 Exelixis Recent Developments/Updates
6.16 Genentech
6.16.1 Genentech Corporation Information
6.16.2 Genentech Kidney Cancer Drugs Description and Business Overview
6.16.3 Genentech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Genentech Kidney Cancer Drugs Product Portfolio
6.16.5 Genentech Recent Developments/Updates
6.17 immatics biotechnologies
6.17.1 immatics biotechnologies Corporation Information
6.17.2 immatics biotechnologies Kidney Cancer Drugs Description and Business Overview
6.17.3 immatics biotechnologies Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.17.4 immatics biotechnologies Kidney Cancer Drugs Product Portfolio
6.17.5 immatics biotechnologies Recent Developments/Updates
6.18 Immunicum
6.18.1 Immunicum Corporation Information
6.18.2 Immunicum Kidney Cancer Drugs Description and Business Overview
6.18.3 Immunicum Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Immunicum Kidney Cancer Drugs Product Portfolio
6.18.5 Immunicum Recent Developments/Updates
6.19 Ono Pharmaceutical
6.19.1 Ono Pharmaceutical Corporation Information
6.19.2 Ono Pharmaceutical Kidney Cancer Drugs Description and Business Overview
6.19.3 Ono Pharmaceutical Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Ono Pharmaceutical Kidney Cancer Drugs Product Portfolio
6.19.5 Ono Pharmaceutical Recent Developments/Updates
6.20 Onyx Therapeutics
6.20.1 Onyx Therapeutics Corporation Information
6.20.2 Onyx Therapeutics Kidney Cancer Drugs Description and Business Overview
6.20.3 Onyx Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Onyx Therapeutics Kidney Cancer Drugs Product Portfolio
6.20.5 Onyx Therapeutics Recent Developments/Updates
6.21 Oxford BioMedica
6.21.1 Oxford BioMedica Corporation Information
6.21.2 Oxford BioMedica Kidney Cancer Drugs Description and Business Overview
6.21.3 Oxford BioMedica Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Oxford BioMedica Kidney Cancer Drugs Product Portfolio
6.21.5 Oxford BioMedica Recent Developments/Updates
6.22 Prometheus Laboratories
6.22.1 Prometheus Laboratories Corporation Information
6.22.2 Prometheus Laboratories Kidney Cancer Drugs Description and Business Overview
6.22.3 Prometheus Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Prometheus Laboratories Kidney Cancer Drugs Product Portfolio
6.22.5 Prometheus Laboratories Recent Developments/Updates
6.23 Seattle Genetics
6.23.1 Seattle Genetics Corporation Information
6.23.2 Seattle Genetics Kidney Cancer Drugs Description and Business Overview
6.23.3 Seattle Genetics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Seattle Genetics Kidney Cancer Drugs Product Portfolio
6.23.5 Seattle Genetics Recent Developments/Updates
6.24 Taiwan Liposome
6.24.1 Taiwan Liposome Corporation Information
6.24.2 Taiwan Liposome Kidney Cancer Drugs Description and Business Overview
6.24.3 Taiwan Liposome Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Taiwan Liposome Kidney Cancer Drugs Product Portfolio
6.24.5 Taiwan Liposome Recent Developments/Updates
6.25 Tracon Pharmaceuticals
6.25.1 Tracon Pharmaceuticals Corporation Information
6.25.2 Tracon Pharmaceuticals Kidney Cancer Drugs Description and Business Overview
6.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Tracon Pharmaceuticals Kidney Cancer Drugs Product Portfolio
6.25.5 Tracon Pharmaceuticals Recent Developments/Updates
6.26 Wilex
6.26.1 Wilex Corporation Information
6.26.2 Wilex Kidney Cancer Drugs Description and Business Overview
6.26.3 Wilex Kidney Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
6.26.4 Wilex Kidney Cancer Drugs Product Portfolio
6.26.5 Wilex Recent Developments/Updates
7 Kidney Cancer Drugs Manufacturing Cost Analysis
7.1 Kidney Cancer Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Kidney Cancer Drugs
7.4 Kidney Cancer Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Kidney Cancer Drugs Distributors List
8.3 Kidney Cancer Drugs Customers
9 Kidney Cancer Drugs Market Dynamics
9.1 Kidney Cancer Drugs Industry Trends
9.2 Kidney Cancer Drugs Market Drivers
9.3 Kidney Cancer Drugs Market Challenges
9.4 Kidney Cancer Drugs Market Restraints
10 Global Market Forecast
10.1 Kidney Cancer Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Kidney Cancer Drugs by Type (2023-2030)
10.1.2 Global Forecasted Revenue of Kidney Cancer Drugs by Type (2023-2030)
10.2 Kidney Cancer Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Kidney Cancer Drugs by Application (2023-2030)
10.2.2 Global Forecasted Revenue of Kidney Cancer Drugs by Application (2023-2030)
10.3 Kidney Cancer Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Kidney Cancer Drugs by Region (2023-2030)
10.3.2 Global Forecasted Revenue of Kidney Cancer Drugs by Region (2023-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
